Lonza’s 4D-Nucleofector System is lifting the Amaxa Nucleofector Technology to the next dimension. Lonza engineers and scientists have developed a system which is designed for maximum flexibility combined with advanced performance and convenience.
Using X-ray crystallography, Penn State researchers have built the first-ever image of a protein interacting with the nucleosome—DNA packed tightly into space-saving bundles organized around a protein core. The research is expected to aid future investigations into diseases such as cancer.
Scientists have discovered a mechanism that plays a critical role in the formation of long-term memory. The findings shed substantial new light on aspects of how memory is formed, and could lead to novel treatments for memory disorders.
Kissing a frog won’t turn it into a prince — except in fairy tales ? but frogs may be hopping toward a real-world transformation into princely allies in humanity’s battle with antibiotic-resistant infections that threaten millions of people worldwide.
Johnson & Johnson's artificial joint business is recalling two hip replacement products, just two days after getting hit with a government warning that it is illegally marketing two other products. It is the 11th J&J recall since September.
IDBS, a worldwide provider of data management and analytics solutions to healthcare organizations, announced that it has concluded an agreement to acquire Quantrix, a company that provides business modeling and analytics software and services.
Momenta Pharmaceuticals, Inc. announced that a judge has denied sanofi-aventis' request for a preliminary injunction directing the FDA to suspend and withdraw its approval of the ANDA filed by Momenta's partner, Sandoz, for a generic version of Lovenox.
PROLOR Biotech, Inc. announced that it has received regulatory clearance from the U.S. Food and Drug Administration to conduct a Phase 2 clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.
Daiichi Sankyo Company, Limited, announced that it has filed for approval in Japan to manufacture and market AMG 162 (denosumab), a gene recombinant drug for bone disorders stemming from bone metastases.
Chelsea Therapeutics International, Ltd. announced confirmation that the U.S. Food and Drug Administration has approved its proposed Phase 2 protocol for CH-4051 in rheumatoid arthritis. Patient screening is to begin next month and treatment starts in October.
Afferent Pharmaceuticals, a biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, announced results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.
According to the agreement, SurModics will develop Edge Therapeutics' lead candidate, Nimogel, a novel biodegradable, site-specific, sustained-release formulation for treatment of delayed complications of ruptured brain aneurysms or traumatic brain injury.
BioTek, a market leader in hybrid microplate detection technology, has released its newest product, the Synergy H1 Hybrid Multi-Mode Microplate Reader.
Thermo Fisher Scientific Inc. announced the launch of its Evolution 200 series of next-generation UV-Visible spectrophotometers featuring new INSIGHT software with CUE (Customized User Environment) scripting capabilities.
Two Cambridge-based organisations, the Wellcome Trust’s Sanger Institute and Horizon Discovery, will collaborate to translate the abundance of new information on human genetic variation into more effective treatments for cancer.